Literature DB >> 25735862

Circulating microRNAs as Promising Tumor Biomarkers.

Meng Chen1, George A Calin2, Qing H Meng3.   

Abstract

microRNAs (miRNAs) are small, nonprotein-coding RNAs that function as posttranscriptional regulators of target genes. miRNAs are involved in multiple cell differentiation, proliferation, and apoptosis processes that are closely related to tumorigenesis. Circulating miRNAs are promising cancer biomarkers under development with great translational potential in personalized medicine. Here, we describe the origin and function of circulating miRNAs and compare the current new high-throughput technology applied to miRNA quantitation. The latest publications on circulating miRNAs were summarized, indicating that miRNAs are potential biomarkers of diagnosis, prognosis, and treatment response of major cancer types including prostate, breast, lung, colorectal, and hematological cancers. We addressed the strengths and limitations of applying circulating miRNAs in clinical laboratory and several issues associated with the accurate measurement of circulating miRNAs.
© 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer diagnosis; Circulating microRNAs; Prognosis; Quantitation; Treatment response; Tumor biomarker

Mesh:

Substances:

Year:  2014        PMID: 25735862     DOI: 10.1016/bs.acc.2014.09.007

Source DB:  PubMed          Journal:  Adv Clin Chem        ISSN: 0065-2423            Impact factor:   5.394


  16 in total

Review 1.  Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Common Solid Tumors: Focus on Lung, Breast, Prostate Cancers, and Osteosarcoma.

Authors:  Michela Bottani; Giuseppe Banfi; Giovanni Lombardi
Journal:  J Clin Med       Date:  2019-10-11       Impact factor: 4.241

Review 2.  Circulating free xeno-microRNAs - The new kids on the block.

Authors:  Linda Fabris; George Adrian Calin
Journal:  Mol Oncol       Date:  2016-01-21       Impact factor: 6.603

Review 3.  MicroRNA aberrations: An emerging field for gallbladder cancer management.

Authors:  Vishal Chandra; Jong Joo Kim; Balraj Mittal; Rajani Rai
Journal:  World J Gastroenterol       Date:  2016-02-07       Impact factor: 5.742

Review 4.  The translational potential of microRNAs as biofluid markers of urological tumours.

Authors:  Annika Fendler; Carsten Stephan; George M Yousef; Glen Kristiansen; Klaus Jung
Journal:  Nat Rev Urol       Date:  2016-11-02       Impact factor: 14.432

5.  Evidence that circulating proteins are more promising than miRNAs for identification of patients with squamous cell carcinoma of the tongue.

Authors:  Linda Boldrup; Giuseppe Troiano; Xiaolian Gu; Philip Coates; Robin Fåhraeus; Torben Wilms; Lena Norberg-Spaak; Lixiao Wang; Karin Nylander
Journal:  Oncotarget       Date:  2017-09-30

Review 6.  Understanding the Role of Non-Coding RNAs in Bladder Cancer: From Dark Matter to Valuable Therapeutic Targets.

Authors:  Cecilia Pop-Bica; Diana Gulei; Roxana Cojocneanu-Petric; Cornelia Braicu; Bogdan Petrut; Ioana Berindan-Neagoe
Journal:  Int J Mol Sci       Date:  2017-07-13       Impact factor: 5.923

Review 7.  MicroRNAs in biofluids are novel tools for bladder cancer screening.

Authors:  Xiaobing Liu; Xin Liu; Yuqi Wu; Qingjian Wu; Qingqing Wang; Zhenxing Yang; Longkun Li
Journal:  Oncotarget       Date:  2017-05-09

8.  Circulating and tissue biomarkers in early-stage non-small cell lung cancer.

Authors:  Caterina Fumagalli; Fabrizio Bianchi; Paola Rafaniello Raviele; Davide Vacirca; Giovanni Bertalot; Cristiano Rampinelli; Matteo Lazzeroni; Bernardo Bonanni; Giulia Veronesi; Nicola Fusco; Massimo Barberis; Elena Guerini-Rocco
Journal:  Ecancermedicalscience       Date:  2017-01-31

9.  Identification of aberrant circulating miRNAs in Parkinson's disease plasma samples.

Authors:  Lei Chen; Junxiu Yang; Jinhui Lü; Shanshan Cao; Qian Zhao; Zuoren Yu
Journal:  Brain Behav       Date:  2018-02-19       Impact factor: 2.708

Review 10.  Cell-to-cell communication: microRNAs as hormones.

Authors:  Recep Bayraktar; Katrien Van Roosbroeck; George A Calin
Journal:  Mol Oncol       Date:  2017-10-26       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.